Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)-A Randomized Pilot Trial

Keyphrases

• Age 50 16%
• Bifidobacterium 16%
• Disease Pathogenesis 16%
• Disease Syndrome 16%
• Fecal Microbiota 16%
• Fecal Samples 16%
• Fibroblast Growth Factor 19 (FGF19) 16%
• Gut Microbiota 16%
• Healthy Population 16%
• Inflammatory Mediators 16%
• Inflammatory Parameters 16%
• Inulin-type Fructans 16%
• Lipopolysaccharide-binding Protein 16%
• Liver 16%
• Liver Fat Content 50%
• Liver Function Tests 16%
• Liver Parameters 16%
• Maltodextrin 16%
• Metabolic Mediators 16%
• Metabolic Parameters 33%
• Metabolic Syndrome 16%
• Non-alcoholic Fatty Liver Disease (NAFLD) 100%
• Placebo 33%
• Placebo Groups 16%
• Prebiotics 100%
• Randomized pilot Trial 100%
• Weight Reduction 16%

Medicine and Dentistry

• Bifidobacterium 16%
• Body Weight 16%
• Fat Content 50%
• Fibroblast Growth Factor 19 16%
• Fructan 16%
• Gut Microbiota 16%
• Inflammatory Mediator 16%
• Inulin 16%
• Lipopolysaccharide Binding Protein 16%
• Liver Function Test 16%
• Maltodextrin 16%
• Metabolic Syndrome 16%
• Nonalcoholic Fatty Liver 100%
• Placebo 50%
• Prebiotics 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Bifidobacterium 20%
• Fatty Liver 60%
• Feces microflora 20%
• Fibroblast Growth Factor 19 20%
• Fructan 20%
• Intestine Flora 20%
• Inulin 20%
• Lipopolysaccharide Binding Protein 20%
• Maltodextrin 20%
• Metabolic Syndrome X 20%
• Nonalcoholic Fatty Liver 100%
• Placebo 60%